FindTrial
Sign In

Research on new diagnostic and therapeutic technologies for renal clear cell carcinoma with high risk of recurrence - combined imaging omics and genomics in personalized precision medicine for tumors

Research on new diagnostic and therapeutic technologies for renal clear cell carcinoma with high risk of recurrence - combined imaging omics and genomics in personalized precision medicine for tumors

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500101537
Enrollment
Unknown
Registered
2025-04-25
Start date
2025-05-01
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal cancer

Interventions

Gold Standard:The high-recurrence-risk group (HR) was defined on the basis of postoperative pathological criteria, including patients meeting any of the following conditions: pT1-2a stage with G3/G4 g
pT2b-4 stage (any grade, N0M0)
any T stage with lymph node metastasis (N1M0) Arterial Grade refers to the specific artery within the renal artery to which the tumor artery belongs: Grade I: main renal artery (if accessory renal ar
Grade II: anterior and posterior branches of the renal artery
Grade III: segmental renal arteries
Grade IV: interlobar arteries
Grade V: branches of the interlobar arteries.
Index test:1.Preoperative laboratory indicators for renal cancer, such as fibrinogen on preoperative blood routine examination. 2.The diameter of the tumor artery and renal artery on DSA

Sponsors

Wenzhou Medical University Affiliated First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 100 Years

Inclusion criteria

Inclusion criteria: (1) Postoperative pathological report confirmed renal clear cell carcinoma; (2) Before surgery, urology enhanced CT and DSA were performed in our hospital, and the image quality was good, meeting the analysis requirements; (3) The clinical data is complete.

Exclusion criteria

Exclusion criteria: (1) Patients undergoing palliative surgery; (2) Received kidney transplant surgery before surgery or was in dialysis status due to renal insufficiency; (3) Patients with bilateral renal cell carcinoma or multiple renal cell carcinoma; (4) Individuals with a history of other types of malignant tumors before surgery.

Design outcomes

Primary

MeasureTime frame
DSA related indicators;Diameter of the tumor artery on the DSA;Diameter of renal artery on DSA;auc cutoff;DCA ;Risk Thresholds, T Net Benefit, NB;Mean Squared Error, MSE Mean Absolute Error, MAE R-squared; C-index Bootstrap Fivefold cross-validation;Accuracy;Sensitivity;Specificity;—

Countries

China

Contacts

Public ContactZhixian Yu

Wenzhou Medical University Affiliated First Hospital

874588531@qq.com+86 198 8468 1686

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026